Therapeutic cancer vaccines aim to generate tumor immunity through coordinated cell- and antibody-mediated responses that ultimately result in highly specific and potent T cells capable of destroying cancers. Cancer vaccines have unique advantages compared to most other cancer therapeutics, with a high degree of specificity for tumor cells relative to normal tissues, a highly favorable side-effect profile, and the potential for a long-lasting treatment effect due to immunologic memory.
KeywordsWhole-cell vaccine Immunotherapy Immune response Chemotherapy Monoclonal antibody Combination immunotherapy
- Emens LA. GM-CSF-secreting vaccines for solid tumors. Curr Opin Invest Drugs. 2009;10:1315–24.Google Scholar
- Emens LA, Jaffee EM. Cancer vaccines: an old idea comes of age. Cancer Biol Ther. 2003;2(4)Suppl 1:S161–8.Google Scholar
- Emens et al. Cancer vaccines in combination with multimodality therapy. Cancer Treat Res. 2005;123:227–45.Google Scholar
- Emens LA, et al. Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation. J Clin Oncol. 2009;27:5911–8.CrossRefPubMedPubMedCentralGoogle Scholar
- Laheru DA, et al. Allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation. Clin Cancer Res. 2008;14:1455–63.CrossRefPubMedPubMedCentralGoogle Scholar
- Van den Eertwegh AJ, et al. Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase I dose-escalation trial. Lancet Oncol. 2012;13:509–17.CrossRefPubMedGoogle Scholar